Toxin won't fix a static line, and the moment every injector recognizes is the two-week review where that becomes somebody's problem. The glabella is quiet. The patient cannot generate the frown at all. And the line is still sitting there, visible at rest, exactly as it was — and the patient is disappointed by a treatment that worked precisely as pharmacology says it should.
Nothing went wrong at the injection. What went wrong happened at the consultation, when a two-component problem was addressed with a one-component plan and nobody said so out loud.
Maritza Mejia builds the second modality into the plan from the first appointment rather than discovering it at review. "Toxin works with the dynamic lines, but it doesn't work with the static lines. Static lines are very deep. That's what we need to work with a different procedure." In her own worked case, the patient gets toxin on day one and a skin-directed treatment two weeks later — and the second appointment is booked before the first one ends.
Why it happens, briefly
A line that appears only on movement is being produced live by the muscle underneath it. Stop the muscle and the line stops. A line visible at rest has passed a threshold: the repeated folding has produced an actual change in the dermis, and that change persists whether or not the muscle is still folding it. The cause was muscular. The finding is now dermal.
Toxin acts on the neuromuscular junction. It does not remodel dermis. If you want the full explanation of the two line types and how to tell them apart at the chair, our dynamic versus static wrinkles guide covers it — this piece is about what to do once you have made that distinction.
The consultation is where this is won
The disappointed review is preventable, and the prevention is a conversation, not a technique.
Show them, do not tell them. Hand the patient a mirror. Ask for a maximal frown, then ask them to relax completely. Point at what remains. "This part" — on movement — "is the muscle. Toxin handles that. This part" — at rest — "is a change in the skin itself. Toxin does not reach that, and nothing I inject into the muscle will." Most patients have never separated the two and will see it immediately.
Better still, capture it. A repose-plus-animation photographic pair makes the distinction undeniable at the two-week review, and it converts an argument into a comparison. Getting that pair right — same lighting, same angle, the same verbal cue for the contraction every time — is the whole point of the standardized photography protocol that governs this kind of plan, covered in its own resource in our treatment-planning cluster.
Name the second modality before the first injection. Not "we might do something else later." Specifically: this is a two-part problem, here is what part one does, here is what part two is, here is roughly when. Maritza's version is simply to schedule it — the skin appointment exists in the calendar before the patient leaves.
Set the clock. This is the part most often skipped and the reason patients quit mid-plan. The dermal component does not improve in two weeks. It improves over a collagen timescale, which means meaningful reassessment at three to four months. A patient who has been told that in advance is patient. A patient who discovers it at review has been surprised twice.
What actually addresses the etched component
The second modality is chosen by what the line is made of, not by what caused it.
Microneedling, as a series. The primary tool for the dermal remodeling the situation calls for. It is not a single appointment and should never be sold as one — the effect builds across sessions spaced a few weeks apart and is assessed on a collagen clock, not a fortnightly one.
A peel, where there is a tonal or surface component. Many etched lines sit in skin that is also dull, roughened or pigmented, and the line reads deeper than it is because of how the surrounding surface handles light. If pigment is part of the picture, leading the skin work with a peel addresses both at once. This is exactly Maritza's reasoning in her worked case: "Why a peel? Because I see some pigmentation in some other areas."
Support underneath, where the line sits over a deficit. A static line crossing a region that has lost underlying volume is partly a shadow. Restoring the support beneath it changes how the line reads without anything touching the line itself. This is a judgment about the compartment below, not about the crease.
Soft product placed superficially, selectively. Some etched lines respond to a low-G-prime product or a skin booster placed in the superficial plane, where the goal is hydration and integration rather than projection. Use this deliberately and conservatively: mobile superficial placement is exactly the context in which product selection and volume discipline matter most, and it is not a first move for every etched line.
Collagen stimulators, where the problem is generalized. If the etched line is one feature of broadly thinned, poor-quality dermis rather than an isolated finding, the answer is a quality strategy across the region rather than a line-directed one. Our overview of facial collagen stimulation covers the principle.
And time with the muscle held quiet. Clinicians commonly observe that established lines soften across repeated toxin cycles, on the reasoning that removing the constant folding lets the dermis do some of its own repair. That is a plausible mechanism and a widely shared clinical impression, and it is worth telling patients that the picture can improve over cycles. It is not, as far as published evidence goes, a demonstrated remodeling effect with a quantified timeline — so offer it as a reasonable expectation, not as a promise.
The order, and why toxin still goes first
Toxin leads even though it is not the treatment that will fix the finding the patient is complaining about. Three reasons:
It removes the ongoing cause. Every day the muscle keeps folding the skin is a day working against whatever dermal remodeling you are trying to achieve. Stopping the folding first means the skin work is not fighting a headwind.
It settles the field for assessment. Once movement is neutralized, what remains at rest is unambiguously the dermal component — which is both easier to treat accurately and easier to photograph and reassess honestly.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Aesthetic & Injectable Training courses — live patients, expert faculty, and ongoing mentorship.
It gives the patient an early win. In a plan whose main payoff is months away, a visible change at two weeks is what keeps the patient in the plan.
The gap between the two is Maritza's standard interval: two to three weeks, primarily so post-injection swelling resolves and the treated areas are left undisturbed. The reasoning behind that interval — including what the drug labels actually say about it, which is nothing — is covered in the waiting-intervals resource in this cluster.
What not to do
Do not add units. The commonest reflex at the disappointed review is to treat the residual line as under-dosing. It is not a dosing problem; it is a category error, and more toxin into a fully relaxed muscle buys nothing except a heavier brow and a patient who dislikes how their forehead moves. If the dosing question itself is genuinely open, our guide to forehead and frontalis dosing covers that separately — but confirm the muscle is actually still active before you reach for it.
Do not inject more superficially to "reach the line." Chasing a dermal finding by changing the plane of a neuromodulator is not a technique, and it trades a predictable result for an unpredictable one.
Do not promise the line will disappear. Etched lines soften. Softening is a good outcome and worth having. Framing it as elimination guarantees a disappointed patient regardless of how well the plan works.
Do not stack the modalities to catch up. The temptation after a disappointing review is to compress — peel and needle in quick succession to show progress. That compromises the barrier and destroys your ability to attribute the result. Space the sessions and let the photographs do the persuading.
The conversation at the two-week review
If you did the consultation properly, this visit is short. You show the animation pair, the muscle is quiet, that part worked. You show the repose pair, you point at the residual line, and you say the thing you already said three weeks ago: this is the part we are treating next, here is what we are doing, here is when we look again.
If you did not do the consultation properly, you are having the whole conversation now with a disappointed patient in front of you, and it will land as an excuse rather than a plan. The content is identical. The credibility is not.
That asymmetry is the argument for building the second modality into the plan from the start — which is really the argument for treating consultation as the part of the appointment where the outcome is decided. As Maritza puts it: "It's not one treatment fits all. Assess your patient, so that way you can deliver the right treatment to your patient."
Reading which component of a line is muscular and which is dermal — and building the plan accordingly — is learned with patients in front of you. Empire Medical Training's Complete Botox Training covers neuromodulator technique hands-on, and Complete Facial Aesthetic Training covers combination facial aesthetics.
Clinical specifics attributed to Maritza Mejia reflect her practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.
About the author. Maritza Mejia, FNP, is a family nurse practitioner, a faculty member at Empire Medical Training, and the founder of Long Island Beauty Bar, New York.
Frequently Asked Questions
Why is a line still visible after toxin has fully worked?
Because the line has two components. Movement produced it, but the repeated folding has changed the dermis, and that change persists once the muscle is quiet. Toxin acts at the neuromuscular junction and does not remodel dermis. A fully relaxed muscle with a residual line at rest is a working treatment, not a failed one.
Should you increase the dose when a static line remains?
No. A residual line over a muscle that cannot contract is not an under-dosing problem, and additional units buy heaviness rather than improvement. Confirm the muscle is genuinely still active before considering dose; if it is not, the remaining finding needs a dermal modality.
What should be added as the second modality?
Whatever matches what the line is made of. Microneedling as a series for dermal remodeling; a peel where pigment or surface quality contribute; support underneath where the line sits over a volume deficit; soft superficial product selectively; or a collagen-stimulator strategy where the dermis is broadly thinned rather than focally etched.
How long after toxin can the skin treatment be done?
Maritza Mejia waits two to three weeks, mainly so post-injection swelling resolves and the injected areas are left undisturbed. No botulinum toxin label specifies an interval before microneedling or peels, so present the interval to patients as your clinical practice rather than as a manufacturer requirement.
When will the patient actually see the etched line change?
Not at the two-week review. Dermal remodeling is assessed on a collagen timescale, with meaningful change at three to four months and a series of sessions behind it. Telling the patient that before the first treatment is what keeps them in the plan long enough to see it.
Disclaimer
This article reflects the clinical opinions and experience of Maritza Mejia, FNP, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.
